Morteza Entezari1, Manuchehr Esmaeili, Mehdi Yaseri. 1. Ophthalmic Research Center, Department of Ophthalmology, Imam Hossein Medical Center, Shahid Beheshti Medical Sciences, Tehran, Iran, entmort@hotmail.com.
Abstract
BACKGROUND: To evaluate the efficacy of intravenous erythropoietin (EPO) on improvement of visual function and color vision in patients with recent indirect traumatic optic neuropathy (TON). METHODS: In a case series, 18 eyes of 18 patients with diagnosis of indirect TON with duration of less than 2 weeks underwent 20,000 IU intravenous EPO injections daily for 3 days. Best corrected visual acuity (BCVA) and color vision were checked by Ishihara test before, 1, and 3 months after injections. BCVA and color vision were compared before, 1, and 3 months after injections. RESULTS: The mean BCVA improved from a baseline of 2.21 ± 0.97 to 1.48 ± 1.29 and 1.31 ± 1.27 log MAR at months 1 and 3, respectively. The differences were statistically significant (P = 0.001, P < 0.001). Color vision was changed from a baseline 2.24 ± 4.29 to 2.94 ± 4.64 and 3.41 ± 5.09 plates at months 1 and 3, respectively. We observed some qualitative improvement that was, however, statistically insignificant at the time of evaluation. (P = 0.063, P = 0.068). CONCLUSION: This case series showed noticeable effect of EPO on improvement of visual function in patients with recent indirect TON.
BACKGROUND: To evaluate the efficacy of intravenous erythropoietin (EPO) on improvement of visual function and color vision in patients with recent indirect traumatic optic neuropathy (TON). METHODS: In a case series, 18 eyes of 18 patients with diagnosis of indirect TON with duration of less than 2 weeks underwent 20,000 IU intravenous EPO injections daily for 3 days. Best corrected visual acuity (BCVA) and color vision were checked by Ishihara test before, 1, and 3 months after injections. BCVA and color vision were compared before, 1, and 3 months after injections. RESULTS: The mean BCVA improved from a baseline of 2.21 ± 0.97 to 1.48 ± 1.29 and 1.31 ± 1.27 log MAR at months 1 and 3, respectively. The differences were statistically significant (P = 0.001, P < 0.001). Color vision was changed from a baseline 2.24 ± 4.29 to 2.94 ± 4.64 and 3.41 ± 5.09 plates at months 1 and 3, respectively. We observed some qualitative improvement that was, however, statistically insignificant at the time of evaluation. (P = 0.063, P = 0.068). CONCLUSION: This case series showed noticeable effect of EPO on improvement of visual function in patients with recent indirect TON.
Authors: Eric L Singman; Nitin Daphalapurkar; Helen White; Thao D Nguyen; Lijo Panghat; Jessica Chang; Timothy McCulley Journal: Mil Med Res Date: 2016-01-11
Authors: Manas R Biswal; Zhaoyao Wang; Ryan J Paulson; Rukshana R Uddin; Yao Tong; Ping Zhu; Hong Li; Alfred S Lewin Journal: Antioxidants (Basel) Date: 2021-05-25